These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 30562637)

  • 1. Methylation of gene CHFR promoter in acute leukemia cells.
    Gong H; Liu W; Zhou J; Xu H
    J Huazhong Univ Sci Technolog Med Sci; 2005; 25(3):240-2. PubMed ID: 16201259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial.
    Ouchi K; Takahashi S; Sasaki K; Yoshida Y; Taniguchi S; Kasahara Y; Komine K; Imai H; Saijo K; Shirota H; Takahashi M; Ishioka C
    Int J Colorectal Dis; 2024 Jun; 39(1):89. PubMed ID: 38862615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHFR: a key checkpoint component implicated in a wide range of cancers.
    Sanbhnani S; Yeong FM
    Cell Mol Life Sci; 2012 May; 69(10):1669-87. PubMed ID: 22159584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear localization of Chfr is crucial for its checkpoint function.
    Kwon YE; Kim YS; Oh YM; Seol JH
    Mol Cells; 2009 Mar; 27(3):359-63. PubMed ID: 19326084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis of poly(ADP-ribose) recognition by the multizinc binding domain of checkpoint with forkhead-associated and RING Domains (CHFR).
    Oberoi J; Richards MW; Crumpler S; Brown N; Blagg J; Bayliss R
    J Biol Chem; 2010 Dec; 285(50):39348-58. PubMed ID: 20880844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer.
    Sanoff HK; Renfro LA; Poonnen P; Ambadwar P; Sargent DJ; Goldberg RM; McLeod H
    PLoS One; 2014; 9(4):e94727. PubMed ID: 24727911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world data on sequencing third-line therapies for metastatic colorectal cancer.
    Bekaii-Saab TS
    Clin Adv Hematol Oncol; 2024 Jun; 22 Suppl 4(5):10-14. PubMed ID: 38805299
    [No Abstract]   [Full Text] [Related]  

  • 8. How best to extend overall survival in metastatic colorectal cancer: Q&A.
    Bekaii-Saab TS; Barzi A; Cusnir M
    Clin Adv Hematol Oncol; 2024 Jun; 22 Suppl 4(5):16-17. PubMed ID: 38805301
    [No Abstract]   [Full Text] [Related]  

  • 9. A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer.
    Kearney MR; Chen EY; Vaccaro GM; Strother J; Burt A; Todd K; Donovan J; Kampa-Schittenhelm KM; Lopez CD
    Anticancer Res; 2019 Jan; 39(1):245-252. PubMed ID: 30591465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHFR promotes metastasis of human gastric carcinoma by activating AKT and ERK via NRF2- ROS axis.
    He F; Ye B; Wu X; Pan J; Wang J; Wang X
    BMC Gastroenterol; 2023 Apr; 23(1):114. PubMed ID: 37024798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic insights in the diagnosis, prognosis, and treatment selection in CRC, an updated review.
    Ghadiri Moghaddam F; Farajnia S; Karbalaei-Mahdi M; Monir L
    Mol Biol Rep; 2022 Oct; 49(10):10013-10022. PubMed ID: 35727475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma.
    González-Borja I; Alors-Pérez E; Amat I; Alonso L; Viyuela-García C; Goñi S; Reyes JC; Ceballos-Chávez M; Hernández-García I; Sánchez-Frías ME; Santamaría E; Razquin S; Arjona-Sánchez Á; Arrazubi V; Pérez-Sanz J; Vera R; Fernández-Irigoyen J; Castaño JP; Viúdez A
    Front Med (Lausanne); 2021; 8():720128. PubMed ID: 34869418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Alterations Upstream and Downstream of p53 Signaling in Colorectal Carcinoma.
    Tomicic MT; Dawood M; Efferth T
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative omics analysis reveals effective stratification and potential prognosis markers of pan-gastrointestinal cancers.
    Jiangzhou H; Zhang H; Sun R; Fahira A; Wang K; Li Z; Shi Y; Wang Z
    iScience; 2021 Aug; 24(8):102824. PubMed ID: 34381964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylation-Based Therapies for Colorectal Cancer.
    Cervena K; Siskova A; Buchler T; Vodicka P; Vymetalkova V
    Cells; 2020 Jun; 9(6):. PubMed ID: 32599894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.
    Cha Y; Kim SY; Yeo HY; Baek JY; Choi MK; Jung KH; Dong SM; Chang HJ
    Neoplasia; 2019 Jan; 21(1):146-155. PubMed ID: 30562637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer.
    Hagiwara T; Sugimoto K; Momose H; Irie T; Honjo K; Okazawa YU; Kawai M; Kawano S; Munakata S; Takahashi M; Kojima Y; Serizawa N; Nagahara A; Hoffman RM; Brock MV; Sakamoto K
    Anticancer Res; 2022 Feb; 42(2):697-707. PubMed ID: 35093868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
    Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS
    Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy.
    Bosch LJ; Luo Y; Lao VV; Snaebjornsson P; Trooskens G; Vlassenbroeck I; Mongera S; Tang W; Welcsh P; Herman JG; Koopman M; Nagtegaal ID; Punt CJ; van Criekinge W; Meijer GA; Monnat RJ; Carvalho B; Grady WM
    Clin Cancer Res; 2016 Sep; 22(18):4612-22. PubMed ID: 27121793
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.